Candriam SCA’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-826,155
| Closed | -$31.7M | – | 701 |
|
|
2023
Q2 | $31.7M | Sell |
826,155
-100,000
| -11% | -$2.57M | 0.23% | 112 |
|
|
2023
Q1 | $19.7M | Hold |
926,155
| – | – | 0.14% | 169 |
|
|
2022
Q4 | $24.3M | Buy |
926,155
+55,000
| +6% | +$1.22M | 0.16% | 148 |
|
|
2022
Q3 | $17.1M | Hold |
871,155
| – | – | 0.12% | 184 |
|
|
2022
Q2 | $15.2M | Sell |
871,155
-314,159
| -27% | -$4.93M | 0.13% | 173 |
|
|
2022
Q1 | $19.4M | Buy |
1,185,314
+80,412
| +7% | +$1.09M | 0.13% | 168 |
|
|
2021
Q4 | $18M | Buy |
1,104,902
+202,365
| +22% | +$2.88M | 0.12% | 189 |
|
|
2021
Q3 | $11.5M | Buy |
902,537
+27,413
| +3% | +$361K | 0.08% | 250 |
|
|
2021
Q2 | $12.4M | Buy |
+875,124
| New | +$14M | 0.08% | 259 |
|
|
2019
Q4 | – | Sell |
-47,800
| Closed | -$253K | – | 810 |
|
|
2019
Q3 | $253K | Hold |
47,800
| – | – | ﹤0.01% | 719 |
|
|
2019
Q2 | $366K | Buy |
47,800
+11,600
| +32% | +$177K | ﹤0.01% | 771 |
|
|
2019
Q1 | $720K | Buy |
+36,200
| New | +$631K | 0.01% | 679 |
|
|
2017
Q2 | – | Sell |
-11,500
| Closed | -$618K | – | 721 |
|
|
2017
Q1 | $618K | Sell |
11,500
-67
| -0.6% | -$3.79K | 0.01% | 628 |
|
|
2016
Q4 | $659K | Hold |
11,567
| – | – | 0.02% | 579 |
|
|
2016
Q3 | $719K | Hold |
11,567
| – | – | 0.02% | 545 |
|
|
2016
Q2 | $654K | Hold |
11,567
| – | – | 0.02% | 515 |
|
|
2016
Q1 | $737K | Sell |
11,567
-109
| -0.9% | -$8.82K | 0.02% | 483 |
|
|
2015
Q4 | $1.64M | Sell |
11,676
-54
| -0.5% | -$7.33K | 0.04% | 328 |
|
|
2015
Q3 | $1.14M | Sell |
11,730
-405
| -3% | -$48.2K | 0.03% | 421 |
|
|
2015
Q2 | $1.84M | Buy |
+12,135
| New | +$2M | 0.04% | 375 |
|
Candriam SCA's KDNY Position: Q3 2023 in Review
Candriam SCA sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 826,155 shares — an estimated $31.7M sold.
Candriam SCA first reported a position in KDNY in Q2 2015 and held it in 20 quarters. The position peaked at $31.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Candriam SCA reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Candriam SCA sold 826,155 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $31.7M.
- Candriam SCA first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 20 quarters.
- Candriam SCA's Chinook Therapeutics, Inc. Common Stock position peaked at $31.7M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.